Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$0.77 - $1.8 $188,656 - $441,016
-245,009 Reduced 34.03%
474,929 $607,000
Q4 2022

Feb 14, 2023

SELL
$0.54 - $1.12 $540,000 - $1.12 Million
-1,000,000 Reduced 58.14%
719,938 $547,000
Q3 2022

Nov 14, 2022

SELL
$0.86 - $1.55 $958,953 - $1.73 Million
-1,115,062 Reduced 39.33%
1,719,938 $1.6 Million
Q2 2022

Aug 15, 2022

BUY
$0.76 - $2.64 $217,360 - $755,040
286,000 Added 11.22%
2,835,000 $2.69 Million
Q1 2022

May 16, 2022

BUY
$1.48 - $6.22 $2.12 Million - $8.93 Million
1,435,000 Added 128.82%
2,549,000 $5.38 Million
Q4 2021

Feb 14, 2022

BUY
$8.77 - $18.29 $865,853 - $1.81 Million
98,729 Added 9.72%
1,114,000 $9.97 Million
Q3 2021

Nov 15, 2021

BUY
$13.54 - $22.06 $7.08 Million - $11.5 Million
522,771 Added 106.15%
1,015,271 $16.9 Million
Q2 2021

Aug 16, 2021

BUY
$14.05 - $25.04 $2.73 Million - $4.86 Million
194,200 Added 65.1%
492,500 $10.2 Million
Q1 2021

May 17, 2021

BUY
$16.57 - $28.65 $2.29 Million - $3.96 Million
138,300 Added 86.44%
298,300 $5.6 Million
Q4 2020

Feb 16, 2021

BUY
$15.44 - $24.23 $592,679 - $930,092
38,386 Added 31.56%
160,000 $3.52 Million
Q3 2020

Nov 16, 2020

SELL
$19.43 - $35.36 $2.08 Million - $3.79 Million
-107,110 Reduced 46.83%
121,614 $2.53 Million
Q2 2020

Aug 14, 2020

SELL
$29.41 - $51.23 $8.85 Million - $15.4 Million
-300,750 Reduced 56.8%
228,724 $8.27 Million
Q1 2020

May 15, 2020

BUY
$19.54 - $55.47 $10.3 Million - $29.4 Million
529,474 New
529,474 $17.3 Million

Others Institutions Holding APLT

About Applied Therapeutics Inc.


  • Ticker APLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,020,700
  • Market Cap $42.3M
  • Description
  • Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...
More about APLT
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.